Frontage Holdings Corporation (HKG:1521)

Hong Kong · Delayed Price · Currency is HKD

1.490

+0.175 (13.31%)

Oct 21, 2026, 4:08 PM HKT

Market Cap	3.03B +34.7%
Revenue (ttm)	2.18B +10.0%
Net Income	83.29M +176.9%
EPS	0.04 +174.7%
Shares Out	2.03B
PE Ratio	36.53
Forward PE	15.31
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,280,000
Open	1.360
Previous Close	1.315
Day's Range	1.335 - 1.500
52-Week Range	0.680 - 1.500
Beta	0.22
Analysts	Strong Sell
Price Target	1.11 (-25.5%)
Earnings Date	Aug 28, 2026

About Frontage Holdings

Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies. It offers drug discovery services comprising medicinal chemistry, pharmacology, and efficacy, as well as absorption, distribution, metabolism, and excretion (ADME) screening. The company also provides drug metabolism and pharmacokinetics (DMPK); safety and toxicology; early phase clinical services; and bioequivalence and related services, such a... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2001

Employees 1,800

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 1521

Full Company Profile

Financial Performance

In 2025, Frontage Holdings's revenue was $256.69 million, an increase of 0.70% compared to the previous year's $254.91 million. Earnings were $6.79 million, an increase of 758.79%.

Financial numbers in USD Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 1521 stock is "Strong Sell." The 12-month stock price target is $1.11, which is a decrease of -25.50% from the latest price.

Price Target

$1.11

(-25.50% downside)

Analyst Consensus: Strong Sell

Stock Forecasts